0.0087USD-2.25%Mkt Cap: —P/E: —2d ago
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of ana…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)2.12M $
Gross Profit-7.66M $
Net Income (TTM)-40.83M $
Revenue/Share0.0110 USD
Last Price0.0087 USD
Fiscal Year End—
MR Quarter—
Employees184
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.08
EPS (TTM)-3.16
EPS (Forward)—
52W Range
0.00533% of range0.1181
52W High0.1181 USD
52W Low0.0053 USD
Profitability
Gross Margin-376.05%
Oper. Margin-6649.26%
EBITDA Margin0.00%
Profit Margin-2003.58%
ROE-1313.38%
ROA-35.09%
Growth
Revenue Growth34.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-105.04M $
CapEx (TTM)884.00K $
FCF Margin-2753.10%
FCF Yield—
Net Debt-13.02M $
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity20.86
Current Ratio6.21
Quick Ratio5.37
Book Value/Sh0.1130 USD
Cash/Share0.2880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float246.35M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta2.47
S&P 52W Chg18.16%
Avg Vol (30d)2.65K
Avg Vol (10d)—
Technical Indicators
RSI (14)1.5
MACD-0.0280
MACD Signal-0.0200
MACD Hist.-0.0079
BB Upper0.1709 USD
BB Middle0.0698 USD
BB Lower-0.0313 USD
BB Width289.77%
ATR (14)0.0050 USD
Vol Ratio (20d)8.56x